A study found that tirzepatide delivered weight loss results of up to 15.7 percent of a patient's body weight, an average of more than 34 pounds.
, causing diabetes patients to go without a medication that manages their condition.
If approved for weight management, tirzepatide could top $50 billion in annual sales, five times the amount of semaglutide medications like Ozempic and Wegovy, which produced nearly $10 billion in sales last year, according to the Associated Press.Semaglutide medications such as Ozempic and Wegovy are glucagon-like peptide 1 agonists that bind to receptors in the pancreas. The medication enhances insulin production, lowering blood sugar in patients with Type 2 diabetes.
Boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17 in Los Angeles. Some doctors prescribe Ozempic off-label to treat obesity.Close to half of American adults, 42 percent, struggle with obesity. Obesity is considered a"major public health problem," and more than 19 percent of the nation's children struggle with it, according to Page.
In addition to their steep price and limited potential when stopped, the drugs come with an assortment of negative side effects such as vomiting and diarrhea. A less common but potentially more serious side effect is pancreatitis.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
New weight loss drug on fast-track to rival Ozempic, WegovyDrugmaker Eli Lilly said it's seeking FDA approval of its drug Mounjaro to treat weight loss after late-stage trials showed unprecedented results.
Baca lebih lajut »
New York, New York Barely Scratches the Surface of New York, New YorkIt doesn’t make it here.
Baca lebih lajut »
Dividend Stocks Under $50 to Consider in 2023 | HackerNoonWe have discussed some great dividend paying stocks for 2023 along with the criteria for filtering them. - stocks stockmarket
Baca lebih lajut »